Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nexavar® In Combination With Chemotherapy Shown To Extend Progression-Free Survival In Patients With Advanced Breast Cancer
Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. announced that their first cooperative group-sponsored randomized Phase II trial in advanced metastatic breast cancer met its primary endpoint of progression-free survival. The study evaluated Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Study findings demonstrated that the median progression-free survival was extended in patients treated with Nexavar and capecitabine compared to patients receiving capecitabine and placebo. These results were statistically significant (p-value = 0.0006). In this trial, the safety and tolerability of the combination was as expected and did not show any new or unexpected toxicities. A complete data analysis from this study is expected to be presented at an upcoming scientific meeting.
generic viagra online
Angiotech Pharmaceuticals Announces Launch Of Quill SRS Product Codes For Laparoscopic Gynecology Procedures
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced the launch of a series of new, proprietary Quill(TM) SRS product codes specifically designed for laparoscopic, or minimally invasive, gynecology procedures, including hysterectomies and myomectomies. In 2008, there were approximately 750,000 hysterectomies performed in the United States of which approximately 130,000 were performed laparoscopically. In addition, there were approximately 72,000 myomectomies performed in the United States to remove uterine fibroid tumors. Management estimates 6-8% annual growth in laparoscopically assisted hysterectomies through 2014.
News of the day
Thousands Of Federal Workers Now Protected From Secondhand Smoke Exposure
American Lung Association Calls Upon President Obama to Protect Entire Federal Workforce
Cardiovascular

New Report Suggests That Zinc Activates A Key Protein On T Cells Needed To Fight Infections

Everyone knows that vitamins "from A to zinc" are important for good health. Now, a new research study in the August 2009 print issue of the Journal of Leukocyte Biology suggests that zinc may be pointing the way to new therapeutic targets for fighting infections. Specifically, scientists from Florida found that zinc not only supports healthy immune function, but increases activation of the cells (T cells) responsible for destroying viruses and bacteria. "It has been shown that zinc supplementation significantly reduces the duration and severity of childhood diarrhea, lower respiratory infections, and incidence of malaria in zinc-deficient children," said report co-author, Robert Cousins, Ph.D., who also is the director of the Center for Nutritional Sciences within the Food Science and Human Nutrition Department at the University of Florida. "Age-related declines in immune function have also been related to zinc deficiency in the elderly." Scientists administered either a zinc supplement or a placebo to healthy volunteers to assess the effects of zinc on T cell activation. After isolating the T cells from the blood, scientists then simulated infection in laboratory conditions. Results showed that T cells taken from the zinc-supplemented group had higher activation than those from the placebo group. Specifically, cell activation stimulated the zinc transporter in T cells called "ZIP8," which transports stored zinc into the cell cytoplasm where it then alters the expression of a T cell protein in a way needed to fight infections. "As the debate over zinc supplementation in healthy individuals continues," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology, "studies like this help shed light on how zinc may enhance the ability of our immune systems to fight off foreign invaders. Equally important, this work points toward new possible targets for entirely new drugs to help augment immune function and prevent or stop infections that might be resistant to traditional antibiotics." Details: Tolunay B. Aydemir, Juan P. Liuzzi, Steve McClellan, and Robert J. Cousins Zinc transporter ZIP8 (SLC39A8) and zinc influence IFN- expression in activated human T cells. J Leukoc Biol 2009 86: 337. http://www.jleukbio.org/cgi/content/abstract/86/2/337 Cody Mooneyhan Federation of American Societies for Experimental Biology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009